AXL1717: Additional Phase I/II data

Additional data from the open-label, dose-escalation, Swedish Phase I/II AXL-001 trial in 49 patients with progressive solid tumors showed that the recommended Phase II dose of AXL1717 was 400 mg given twice daily in a 28-day treatment cycle. In 15 evaluable patients with non-small cell lung cancer (NSCLC), AXL1717 produced 1 partial response. Median survival was 44 weeks and time to progression was 30 weeks in the subgroup. Data were presented at the European Multidisciplinary Cancer meeting in Stockholm. ...